Use of DDAVP in inherited and acquired platelet dysfunction
作者:
Donna M. Dimichele,
Wm. E. Hathaway,
期刊:
American Journal of Hematology
(WILEY Available online 1990)
卷期:
Volume 33,
issue 1
页码: 39-45
ISSN:0361-8609
年代: 1990
DOI:10.1002/ajh.2830330108
出版商: Wiley Subscription Services, Inc., A Wiley Company
关键词: desmopressin;platelet function tests;platelet aggregation;von Willebrand factor;DDAVP
数据来源: WILEY
摘要:
AbstractTwenty‐one patients with prolonged bleeding times secondary to inherited disorders of platelet function and eight patients with prolonged bleeding times secondary to acquired platelet dysfunction were given 0.3 μg per kilogram of DDAVP, 1‐deamino‐8‐D‐arginine vasopressin, intravenously. Sixteen of twenty‐two DDAVP trials in patients with inherited platelet dysfunction (73%) and seven of the nine DDAVP trials in patients with acquired platelet dysfunction (78%) resulted in normalization or shortening of the prolonged bleeding times by at least 4 min. The bleeding time response did not correlate with changes in the levels of von Willebrand factor (vWf) antigen or ristocetin cofactor activity, nor was it associated with changes in vWf multimeric analysis or in vitro platelet aggregations following the administration of DDAVP. Shortening of the bleeding time with DDAVP was seen in patients with a failure to release/storage pool type defect, thromboxane synthesis type defect, Bernard‐Soulier syndrome, Glanzmann's thrombasthenia, the May‐Hegglin anomaly, liver disease, nonuremic renal disease, myelofibrosis, and T
点击下载:
PDF
(648KB)
返 回